Selective antagonist of formyl peptide receptor 2 (FPR2) signaling. Inhibits WKYMVm binding to FPR2 (IC50 = 0.23 μM) and inhibits intracellular calcium release induced by WKYMVm, MMK 1, amyloid β42, and F peptide. Also inhibits FPR2-mediated signaling in human neutrophils; blocks chemotactic migration and superoxide generation by amyloid β42 peptide.

This is a HLA-A*0201 restricted epitope used in melanoma studies.

Danshenxinkun A, Danshenxinkun B and Neocryptotanshinone may intervene thrombotic diseases by adjusting the targets mainly involved in pathways of endocrine system, signal transduction, signaling molecules and interaction, cell motility, environmental adaptation and nervous system.